Vasaloc™ for Diabetic Nephropathy
Vasaloc™ will be developed as an existing oral drug that will be a new treatment for diabetic nephropathy - a progressive complication of diabetes that leads to end-stage renal disease (ESRD) requiring kidney transplantation or chronic dialysis. Current treatment that includes controlling blood sugar, hypertension, blood lipids, etc. can help slow, but not stop, the progression toward ESRD. Vasaloc™ is a repositioned compound based on a low-dose formulation of the approved drug, danazol. As this compound is also formulated in Optina™, we will evaluate Vasaloc™ for further clinical trials after completion and evaluation of the Optina™ trial.
« back to products page
Learn More About:
Premature Ejaculation (PE)
Premature ejaculation is a distressing male sexual dysfunction that is more common than erectile dysfunction (ED) and has a major impact on the quality of life for men and their sexual partners.
Diabetic Retinopathy
A complication of diabetes mellitus that damages the retina in the eyes and leads to blindness
Diabetic Nephropathy
A progressive complication of diabetes mellitus that leads to end-stage renal disease (ESRD) requiring kidney transplantation or chronic dialysis
| AMPE Stock Quote - delayed | ||
| Last | Change | |
| AMPE | 3.59 |  0.07 (1.91%) |
Ampio News
02/09/2012 | Press Release
Ampio Pharmaceuticals Reports Full-Year 2011 Financial Results and Milestone Highlights for 2011
01/31/2012 | Press Release
01/26/2012 | News